A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence
- PMID: 10991938
- DOI: 10.1074/jbc.M004424200
A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence
Abstract
Estrogen antagonists inhibit cell cycle progression in estrogen-responsive cells, but the molecular mechanisms are not fully defined. Antiestrogen-mediated G(0)/G(1) arrest is associated with decreased cyclin D1 gene expression, inactivation of cyclin D1-cyclin dependent kinase (Cdk) 4 complexes, and decreased phosphorylation of the retinoblastoma protein (pRb). We now show that treatment of MCF-7 breast cancer cells with the pure estrogen antagonist ICI 182780 results in inhibition of cyclin E-Cdk2 activity prior to a decrease in the G(1) to S phase transition. This decrease was dependent on p21(WAF1/Cip1) since treatment with antisense oligonucleotides to p21 attenuated the effect. Recruitment of p21 to cyclin E-Cdk2 complexes was in turn dependent on decreased cyclin D1 expression since it was apparent following treatment with antisense cyclin D1 oligonucleotides. To define where within the G(0) to S phase continuum antiestrogen-treated cells arrested, we assessed the relative abundance and phosphorylation state of pocket protein-E2F complexes. While both pRb and p107 levels were significantly decreased, p130 was increased 4-fold and was accompanied by the formation of p130.E2F4 complexes and the accumulation of hyperphophorylated E2F4, putative markers of cellular quiescence. Thus, ICI 182780 inhibits both cyclin D1-Cdk4 and cyclin E-Cdk2 activity, resulting in the arrest of MCF-7 cells in a state with characteristics of quiescence (G(0)), as opposed to G(1) arrest.
Similar articles
-
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.J Biol Chem. 1997 Apr 18;272(16):10882-94. doi: 10.1074/jbc.272.16.10882. J Biol Chem. 1997. PMID: 9099745
-
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry.Mol Cell Biol. 1998 Aug;18(8):4499-508. doi: 10.1128/MCB.18.8.4499. Mol Cell Biol. 1998. PMID: 9671459 Free PMC article.
-
Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.Mol Cell Biol. 2001 Feb;21(3):794-810. doi: 10.1128/MCB.21.3.794-810.2001. Mol Cell Biol. 2001. PMID: 11154267 Free PMC article.
-
Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.Endocr Relat Cancer. 2003 Jun;10(2):179-86. doi: 10.1677/erc.0.0100179. Endocr Relat Cancer. 2003. PMID: 12790780 Review.
-
Cell cycle and transcriptional control of human myeloid leukemic cells by transforming growth factor beta.Leuk Lymphoma. 2000 Jul;38(3-4):235-46. doi: 10.3109/10428190009087015. Leuk Lymphoma. 2000. PMID: 10830731 Review.
Cited by
-
Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.Cancer Res. 2008 Jul 15;68(14):5628-38. doi: 10.1158/0008-5472.CAN-07-3170. Cancer Res. 2008. PMID: 18632615 Free PMC article.
-
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.Breast Cancer Res. 2016 Feb 9;18(1):17. doi: 10.1186/s13058-015-0661-5. Breast Cancer Res. 2016. PMID: 26857361 Free PMC article. Review.
-
Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells.Mol Cell Biol. 2012 Apr;32(8):1483-95. doi: 10.1128/MCB.05245-11. Epub 2012 Feb 13. Mol Cell Biol. 2012. PMID: 22331469 Free PMC article.
-
BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists.EMBO J. 2004 Jun 2;23(11):2293-303. doi: 10.1038/sj.emboj.7600231. Epub 2004 May 13. EMBO J. 2004. PMID: 15141164 Free PMC article.
-
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.Drug Des Devel Ther. 2018 Feb 16;12:321-330. doi: 10.2147/DDDT.S137783. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29497278 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials